RU2016126423A - Композиции и способы лечения внутримозгового кровоизлияния - Google Patents

Композиции и способы лечения внутримозгового кровоизлияния Download PDF

Info

Publication number
RU2016126423A
RU2016126423A RU2016126423A RU2016126423A RU2016126423A RU 2016126423 A RU2016126423 A RU 2016126423A RU 2016126423 A RU2016126423 A RU 2016126423A RU 2016126423 A RU2016126423 A RU 2016126423A RU 2016126423 A RU2016126423 A RU 2016126423A
Authority
RU
Russia
Prior art keywords
less
ich
mmhg
leu
seq
Prior art date
Application number
RU2016126423A
Other languages
English (en)
Russian (ru)
Other versions
RU2016126423A3 (OSRAM
Inventor
Стивен АРКИН
Хоаким ФРУБИС
Маркус И. КАРР
Санита ХЕТТ
Реема ДЖАСУДЖА
Дебра Д. ПИТТМАН
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of RU2016126423A publication Critical patent/RU2016126423A/ru
Publication of RU2016126423A3 publication Critical patent/RU2016126423A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2016126423A 2014-01-24 2015-01-15 Композиции и способы лечения внутримозгового кровоизлияния RU2016126423A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931071P 2014-01-24 2014-01-24
US61/931,071 2014-01-24
PCT/IB2015/050313 WO2015110939A1 (en) 2014-01-24 2015-01-15 Compositions and methods for treating intracerebral hemorrhage

Publications (2)

Publication Number Publication Date
RU2016126423A true RU2016126423A (ru) 2018-03-01
RU2016126423A3 RU2016126423A3 (OSRAM) 2018-03-01

Family

ID=52630418

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016126423A RU2016126423A (ru) 2014-01-24 2015-01-15 Композиции и способы лечения внутримозгового кровоизлияния

Country Status (18)

Country Link
US (2) US20160375109A1 (OSRAM)
EP (1) EP3096779B1 (OSRAM)
JP (1) JP6624787B2 (OSRAM)
KR (3) KR20160093731A (OSRAM)
CN (2) CN105934250A (OSRAM)
AU (1) AU2015208819B2 (OSRAM)
BR (1) BR112016014617A2 (OSRAM)
CA (1) CA2937418A1 (OSRAM)
DK (1) DK3096779T3 (OSRAM)
ES (1) ES2772802T3 (OSRAM)
HU (1) HUE047588T4 (OSRAM)
IL (1) IL246637A0 (OSRAM)
MX (1) MX375355B (OSRAM)
PL (1) PL3096779T3 (OSRAM)
PT (1) PT3096779T (OSRAM)
RU (1) RU2016126423A (OSRAM)
SI (1) SI3096779T1 (OSRAM)
WO (1) WO2015110939A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150103205A (ko) 2013-01-31 2015-09-09 화이자 인코포레이티드 인자 Xa 억제를 길항하기 위한 조성물 및 방법
SG11201601221XA (en) 2013-09-24 2016-04-28 Pfizer Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570330A1 (en) * 2004-06-21 2005-12-29 Novo Nordisk Health Care A/S Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich)
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
CN101918025A (zh) * 2008-01-18 2010-12-15 诺沃-诺迪斯克保健股份有限公司 因子Ⅶa或因子Ⅶa等同物用于防止或减弱选择的脑内出血患者亚群在脑内出血(ICH)后出血增多和/或水肿形成的用途
JP6163304B2 (ja) * 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
WO2011020866A2 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US9371522B2 (en) * 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
SG11201500579SA (en) * 2012-07-25 2015-02-27 Catalyst Biosciences Inc Modified factor x polypeptides and uses thereof
KR20150103205A (ko) * 2013-01-31 2015-09-09 화이자 인코포레이티드 인자 Xa 억제를 길항하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
PT3096779T (pt) 2020-02-21
CN105934250A (zh) 2016-09-07
IL246637A0 (en) 2016-08-31
JP6624787B2 (ja) 2019-12-25
ES2772802T3 (es) 2020-07-08
SI3096779T1 (sl) 2020-03-31
KR20210008177A (ko) 2021-01-20
PL3096779T3 (pl) 2020-05-18
EP3096779B1 (en) 2019-12-18
DK3096779T3 (da) 2020-02-24
CN112156176A (zh) 2021-01-01
RU2016126423A3 (OSRAM) 2018-03-01
US20190231856A1 (en) 2019-08-01
CA2937418A1 (en) 2015-07-30
BR112016014617A2 (pt) 2017-09-19
US20160375109A1 (en) 2016-12-29
WO2015110939A1 (en) 2015-07-30
KR20180014221A (ko) 2018-02-07
MX2016009665A (es) 2016-11-14
KR20160093731A (ko) 2016-08-08
AU2015208819A1 (en) 2016-06-30
EP3096779A1 (en) 2016-11-30
HUE047588T4 (hu) 2020-06-29
JP2015147764A (ja) 2015-08-20
HUE047588T2 (hu) 2020-04-28
AU2015208819B2 (en) 2020-01-23
MX375355B (es) 2025-03-04

Similar Documents

Publication Publication Date Title
US20180099027A1 (en) Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
Cerri et al. Chemokines as new inflammatory players in the pathogenesis of epilepsy
JP7096592B2 (ja) Ｊａｋ阻害剤およびこれらの利用
RU2707191C2 (ru) Нейродегенеративные расстройства
Wang et al. Glimepiride and glibenclamide have comparable efficacy in treating acute ischemic stroke in mice
Akyuz et al. Effect of early bilateral decompressive craniectomy on outcome for severe traumatic brain injury.
EP3463575B1 (en) Methods and compositions for modulating lymphatic vessels in the central nervous system
EA201291103A1 (ru) Композиции гуанилатциклазы и способы лечения врожденного амавроза лебера типа 1 (lca1)
Park et al. The effect of melatonin on retinal ganglion cell survival in ischemic retina
CN101288768A (zh) 用于治疗渐进神经退化症的医药组合物
JP2020502140A (ja) 糖尿病を治療するための新しい方法
Faraji et al. Harnessing BDNF signaling to promote resilience in aging
Hou et al. Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis
Tang et al. TREM2 alleviates long-term cognitive dysfunction after subarachnoid hemorrhage in mice by attenuating hippocampal neuroinflammation via PI3K/Akt signaling pathway
US9060977B2 (en) Heparin binding epidermal growth factor (HB-EGF) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation
Shi et al. EA participates in pain transition through regulating KCC2 expression by BDNF-TrkB in the spinal cord dorsal horn of male rats
EP3506925B1 (en) Use of cgrp receptor antagonists in treating glaucoma
WO2017180841A1 (en) Treatment of cerebral cavernous malformations
JP2015147764A5 (OSRAM)
US20190002517A1 (en) Neuropeptide y-derived peptides
MX2021003123A (es) Isomeros rotomericos de 4-alquil-5-heteroaril-3h-1,2-ditiol-3-tion as.
WO2015121428A1 (en) Polypeptide fragments of 168a-t2 and compositions comprising them for use in treating cancer
Lu et al. The prognostic utility of no evidence of disease activity (neda)
Ostroukhova et al. Migraine and orexin
TWI306770B (en) Pharmaceutical composition for rescuring learning or memory deficits

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190121